Gilead Sciences, Inc. (GILD) Shares Sold by Doyle Wealth Management

Doyle Wealth Management reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 145,198 shares of the biopharmaceutical company’s stock after selling 2,193 shares during the period. Gilead Sciences makes up approximately 1.8% of Doyle Wealth Management’s portfolio, making the stock its 22nd biggest position. Doyle Wealth Management’s holdings in Gilead Sciences were worth $10,402,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in Gilead Sciences by 2.4% during the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after purchasing an additional 2,148,697 shares during the period. FMR LLC increased its stake in Gilead Sciences by 1.1% during the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after purchasing an additional 258,005 shares during the period. Parnassus Investments CA increased its stake in Gilead Sciences by 2.5% during the fourth quarter. Parnassus Investments CA now owns 19,159,748 shares of the biopharmaceutical company’s stock worth $1,372,604,000 after purchasing an additional 464,609 shares during the period. Northern Trust Corp increased its stake in Gilead Sciences by 0.7% during the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after purchasing an additional 116,780 shares during the period. Finally, Capital International Investors increased its stake in Gilead Sciences by 86.6% during the third quarter. Capital International Investors now owns 11,217,015 shares of the biopharmaceutical company’s stock worth $908,803,000 after purchasing an additional 5,205,983 shares during the period. Hedge funds and other institutional investors own 77.83% of the company’s stock.

How to Become a New Pot Stock Millionaire

Gilead Sciences stock opened at $72.84 on Friday. The company has a quick ratio of 2.67, a current ratio of 2.74 and a debt-to-equity ratio of 1.53. The stock has a market capitalization of $98,994.28, a P/E ratio of 20.93, a P/E/G ratio of -1.74 and a beta of 1.24. Gilead Sciences, Inc. has a fifty-two week low of $63.76 and a fifty-two week high of $89.54.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.67 by $0.11. The firm had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The firm’s quarterly revenue was down 18.7% compared to the same quarter last year. During the same period in the prior year, the company posted $2.70 earnings per share. equities analysts anticipate that Gilead Sciences, Inc. will post 6.21 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be issued a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 3.13%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Thursday, March 15th. Gilead Sciences’s dividend payout ratio is 65.52%.

GILD has been the topic of a number of recent research reports. Leerink Swann reiterated a “market perform” rating and set a $80.00 price target (down from $83.00) on shares of Gilead Sciences in a research note on Thursday, February 22nd. Credit Suisse Group reiterated a “buy” rating and set a $82.00 price target on shares of Gilead Sciences in a research note on Thursday, December 7th. Zacks Investment Research lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, December 27th. ValuEngine upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. Finally, Wells Fargo upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $79.02 to $96.00 in a research note on Tuesday, January 16th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $88.61.

In related news, Director John Francis Cogan sold 5,833 shares of the company’s stock in a transaction that occurred on Friday, March 16th. The stock was sold at an average price of $80.09, for a total value of $467,164.97. Following the completion of the transaction, the director now directly owns 58,452 shares of the company’s stock, valued at $4,681,420.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John C. Martin sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $73.62, for a total value of $3,681,000.00. Following the completion of the transaction, the insider now directly owns 3,046,766 shares of the company’s stock, valued at $224,302,912.92. The disclosure for this sale can be found here. Insiders sold 436,101 shares of company stock valued at $34,541,560 over the last ninety days. 1.30% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: “Gilead Sciences, Inc. (GILD) Shares Sold by Doyle Wealth Management” was first reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3298561/gilead-sciences-inc-gild-shares-sold-by-doyle-wealth-management.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

First Internet Bancorp’s  Buy Rating Reiterated at Maxim Group
First Internet Bancorp’s Buy Rating Reiterated at Maxim Group
Show  Reaches Market Cap of $0.00
Show Reaches Market Cap of $0.00
PayCoin  Price Tops $0.0344 on Major Exchanges
PayCoin Price Tops $0.0344 on Major Exchanges
UGAIN Price Reaches $0.0031
UGAIN Price Reaches $0.0031
Reviewing Sally Beauty  and Kirkland’s Home
Reviewing Sally Beauty and Kirkland’s Home
Comparing CGG  and Paramount Resources
Comparing CGG and Paramount Resources


© 2006-2018 Ticker Report. Google+.